<DOC>
	<DOCNO>NCT02865850</DOCNO>
	<brief_summary>A multicenter , randomize , open-label , active-controlled Phase 3 study correction anemia maintenance HGB subject DD-CKD .</brief_summary>
	<brief_title>Efficacy Safety Study Evaluate Vadadustat Correction Anemia Subjects With Incident Dialysis-dependent Chronic Kidney Disease ( DD-CKD )</brief_title>
	<detailed_description>This multicenter , randomize , open-label , active-controlled Phase 3 study efficacy safety vadadustat versus darbepoetin alfa correction anemia maintenance HGB subject anemia secondary CKD recently initiate dialysis treatment end-stage renal disease .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>â‰¥18 year age Initiated chronic maintenance dialysis ( either peritoneal hemodialysis ) endstage kidney disease within 16 week prior Screening Mean Screening hemoglobin &lt; 10.0 g/dL Received 1 dose longacting ( eg , darbepoetin alfa , methoxy polyethylene glycolepoetin beta [ Mircera , C.E.R.A . ] ) 2 dos short act erythropoiesisstimulating agent ( ESA ) ( eg , recombinant human erythropoietin [ rHuEPO ] ) within 8 week prior Screening . Subjects may receive ESA Screening period Uncontrolled hypertension Severe heart failure Screening ( New York Heart Association Class IV ) Acute coronary syndrome ( hospitalization unstable angina myocardial infarction ) , urgent coronary revascularization , hospitalization CHF , stroke within 12 week prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>vadadustat</keyword>
	<keyword>AKB-6548</keyword>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>kidney</keyword>
	<keyword>renal</keyword>
	<keyword>oral anemia treatment</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>hypoxia-inducible factor</keyword>
	<keyword>HIF</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>phase 3</keyword>
	<keyword>cardiovascular</keyword>
</DOC>